Exclusive Online Content
Recursion Bridges the Protein & Chemical Space With Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion recently announced it has successfully screened the Enamine REAL Space chemical library using its MatchMaker technology, recently acquired from Cyclica, to predict the protein target(s) for….
Silo Pharma Reaches Positive Milestone With Nasal Formulation for Anxiety, PTSD & Stress-Related Disorders
Silo Pharma, Inc. recently announced it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in….
Sygnature Discovery Accelerates Global Growth With Major North American Acquisition
Leading integrated drug discovery partner, Sygnature Discovery, recently announced its acquisition of one of North America’s largest discovery Contract Research Organizations, Canada-based….
ProQR Therapeutics & Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen & Ultevursen Ophthalmic Assets
ProQR Therapeutics N.V. and Laboratoires Théa recently announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and….
Ocean Biomedical, Inc. Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
On World Lung Cancer Day, Ocean Biomedical, Inc. is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits….
Mitsubishi Gas Chemical Develops First-Ever, PFAS-Free Oxygen Absorber to Help the Industry Meet Emerging Global Regulations
In response to the growing legislation around per- and polyfluoroalkyl substances (PFAS), Mitsubishi Gas Chemical (MGC) has launched the first future-proof, eco-friendly packaging solution for the industry using a cleaner chemistry within record-breaking turnaround…..
Bora Pharmaceuticals Unveils Eye-Opening New Facility for Ophthalmic Manufacturing
Bora Pharmaceuticals recently announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan. Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of….
First Wave BioPharma Announces Initial Topline Results From Phase 2 Trial Investigating Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced it has received topline results from its Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic….
George Medicines Completes Recruitment of first Phase 3 Hypertension Trial Investigating Novel Single-Pill Triple Combination Candidate
George Medicines recently announced all patients have been enrolled in its Phase 3 active-controlled trial evaluating the efficacy and safety of GMRx2, the company’s….
Gerresheimer Launches Open Innovation Program for the Development of Home Therapy Solutions
As an innovative system and solution provider, Gerresheimer is the global partner for the pharma and biotech industry. In collaboration with ekipa, a leading incubator for open innovation, Gerresheimer is calling on start-ups, companies, students, researchers, and….
EXCLUSIVE ONLINE CONTENT
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….